CLINICAL MANIFESTATION, APPLICATION, TREATMENT PATTERN AND SAFETY ANALYSIS OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE

KRISHNA JEE[1], SHIVANSHI SAINI[2], ARPIT KUMAR SHARMA[3], MOHD KASHIF[4], SHIVANI[5], BHARATI MALIK[6], ANNAPURNA TYAGI[7] BHAWANA KORANGA[8]

1. ASSISTANT PROFESSOR (DEPARTMENT OF PHARMACEUTICAL CHEMISTRY), ROORKEE COLLEGE OF PHARMACY, ROORKEE, UTTARAKHAND, INDIA

2. RESEARCH SCHOLAR (DEPARTMENT OF PHARMACEUTICS). TEERTHANKAR MAHAVEER UNIVERSITY, MORADABAD, UTTAR PRADESH, INDIA

3. RESEARCH SCHOLAR (DEPARTMENT OF PHARMACEUTICS). TEERTHANKAR MAHAVEER COLLEGE OF PHARMACY, MORADABAD, UTTAR PRADESH, INDIA

4. ASSOCIATE PROFESSOR (DEPARTMENT OF PHARMACOLOGY), ROORKEE COLLEGE OF PHARMACY, ROORKEE, UTTARAKHAND, INDIA

5. M.PHARMA STUDENT (DEPARTMENT OF PHARMACEUTUCAL CHEMISTRY), HIMALAYAN INSTITUTE OF PHARMACY AND RESEARCH, DEHRADUN, UTTARAKHAND, INDIA

6. M.PHARMA STUDENT (DEPARTMENT OF PHARMACOGNOSY), TRANSLAM INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH, MEERUT, UTTAR PRADESH, INDIA

7. ASSISTANT PROFESSOR (DEPARTMENT OF PHARMACOLOGY), ROORKEE COLLEE OF PHARMACE, ROORKEE, UTTARAKHAND, INDIA

8. M.PHARMA STUDENT (DEPARTMENT OF PHARMACEUTICS), NKBR COLLEGE OF PHARMACY & RESEARCH CENTRE, MEERUT, UTTAR PRADESH, INDIA

1. infokrishnajee1997@rcpcollege.edu.in **2.**shivanshisaini08@gmail.com **3.**assharma426.as@gmail.com**4.**kashifpharmafreind@gmail.com**5.**shivanipegowal28@gmail.com**6.**bharatimalik1712@gmail.com**7.**annapurnatyagi623@gmail.com**8.**bhawanakoranga122@gmail.com

ABSTRACT-

Vedolizumab has been found to have unusual gut selectivity features in clinical studies, and these properties may help explain why the drug has a favourable benefit-risk profile. In this review, we present data onClinical Manifestation, Application Treatment pattern and Safety Analysis of Vedolizumab.

A recurrent and remitting clinical history, chronic inflammation, the requirement for lifelong medication, and usually significant morbidity are the hallmarks of Crohn's disease (CD), ulcerative colitis (UC), and other inflammatory bowel disorders (IBD).

A percentage of gastrointestinal-homing T lymphocytes express the 47 integrin, which vedolizumab, an integrin antagonist, binds to the mucosal contact information in ligand binding physiological standpoint, which is expressed on the outer surface of gastrointestinal endothelial cells, is a key element of the gut-specific homing pathway for macrophages.Irritable bowel syndrome (ibs illnesses can be treated with the anti-integrin medication Natalizumab as well as other immunotherapies, such as those that block tumour necrosis factor, work systemically or on a variety of targets which reduce inflammation.

KEYWORD'S-

Irritable Bowel Syndrome (IBS), Tumor Necrosis Factor (TNF), Ulcerative Colitis (UC), Vedolizumab (VDZ), Crohn's Disease (CD),Inflammatory Bowel Disease (IBD).

1. INTRODUCTION-

Inflammatory Bowel Disease or irritable bowel syndrome refers to a collection of illnesses that develop when the colon and tiny intestine develop inflamed.The two most common types are Crohn's disease and ulcerative colitis.Inflammatory cells that invade the gut and mucosal tissue are its defining feature.[2] Immuno-suppressants such azathioprine, mercaptopurine, methotrexate, and glucocorticoids are being used in the treatment of UC and CD.[3] Previously known as LDP-02, MLN-02, and MLN0002, vedolizumab is a conjugated antibody that binds to the 4-7integrin and regulates the migration of memory T cells further into irritable gut and intestinal regions.[4,5] In addition, long-term, repeated, or high-dose corticosteroid use—common in the elderly population—can exacerbate a variety of cardiac metabolic and mental health conditions. Diabetes mellitus has also been linked to elderly patients using oral corticosteroids.[6,7] Vedolizumab, an immunoglobulin G1 monoclonal antibody to the α4β7 integrin that has been humanised, particularly decreases inflammation in the gastrointestinal tract while having no impact on systemic immune responses.[8] Vedolizumab safety and efficacy for moderately to highly active UC and CD, respectively, were established in the phase 3 GEMINI 1 and GEMI 2 trials.[9,10] The Vedolizumab Clinical Decision Support Tool (VDZCDST) was created with the intention of predicting the medication's efficacy in CD patients. 6 The VDZ-CDST combines serum C-reactive protein (CRP) levels, no history of bowel operations, anti-TNF (Tumor Necrosis Factor) exposure in the past, no history of a fistulising sickness, and albumin levels. These five criteria have been associated to better response rates to VDZ.[11,12] Twenty to forty percent of patients who get effective treatment with anti-TNF alpha medications do not react to induction therapy, and of the twenty to thirty percent of patients who achieve remission, thirty to forty percent will later lose their response.[13,14,15]Currently, the only integrin interactions antagonists utilised in therapeutic situations are Natalizumab and vedolizumab, which work to block integrin's from binding to their endothelium ligands.[16,17]

Drug	Target	Indication	Gut Selectivity
Vedolizumab	α_4 β_7 Integrin	UC, CD	Yes
Natalizumab	α_4 Integrin	CD	No
Golimumab	TNF α	UC	No
Infliximab	TNF α	UC, CD	No
Pegol Certolizumab	TNF α	CD	No
Adalimumab	TNF α	UC, CD	No

Table 1. Medical Treatments for UC and CD Using Biological Methods

2. TREATMENT PATTERN FOR CD-

Treatment options for CD patients include dietary and lifestyle modifications, medication, surgery, and extra (e.g., nutritional) therapies. In this review, only the use of pharmacological treatments, Clinical safety and effectiveness was included. A summary of this study is to reported patients characteristic and outcomes. The three therapeutic groups that are most frequently administered are immunomodulators, corticosteroids, and 5-ASA. In both the UK and Denmark, there have been reports of rising immunomodulators prescription rates, declining surgery rates, and lowering 5-ASA and corticosteroid prescription rates.[18,19]

3. CLINICAL MANIFESTATION OF CD

Clinical signs of CD might include weight loss, malnutrition, stomach discomfort, and diarrhoea or bloody diarrhoea. Extra intestinal findings, including skin conditions or arthropathy, can also manifest and significantly affect the patient's quality of life.[20,21]

CD is characterised by a pattern of assaults, recurrent episodes, long-term destruction to the intestinal epithelium (if not successfully treated), and intervals of respite or less severe sickness, which progresses over time with a history of assaults. It is important to distinguish between active treatment of acute illness and avoiding recurrence (maintaining remission).[22]Medication treatment aims to minimise symptoms, uphold or enhance the standard of living, and lower short- and long-term drug toxicity. It is suggested that glucocorticoids (budesonide) be used as the first line of treatment for CD.

When the situation is significant, persistent CD has not improved with traditional therapy, as well as the glucocorticoids dose can indeed be lowered, TNF- inhibitors (such as infliximab) and/or immune-modulators are used as add-on therapies to glucocorticoids. 3 Other medications with different modes of action have recently been under development, such as integrin inhibitors, humanised monoclonal antibodies that target interleukin-12 and interleukin-23, and Janus kinase inhibitors (e.g., Vedolizumab).[23] The effectiveness of CD's medical treatment has now been examined in a number of clinical investigations.To determine whether the drugs used to treat CD are clinically effective and safe, systematic literature reviews and meta-analyses were conducted. Budesonide was reportedly not any more beneficial than a placebo for maintaining remission, according to a meta-analysis of 12 clinical research; nevertheless. The overall quality of the evidence was extremely poor due to a lack of data and significant bias risks (single-blind, non-concealed allocation).[24]In a second meta-analysis, 27 studies were included, and anti-TNF antibodies were found to cause luminal CD to remit more effectively than a placebo.Furthermore, the prevention of luminal CD reappearance was improved by anti-TNF immunoglobulin compared to a placebo.[25,26]

4. CLINICAL EFFECTIVENESS OR SAFETY ANALYSIS-

The classification of adverse events was performed using the Medical Dictionary for Regulatory Activities (MedDRA), version 14.0.[27,28] A clinical response to and clinical remission from Vedolizumab were greater than those achieved with the placebo in UC patients.[29] Those with moderate-to-severe UC who don't respond to corticosteroids, immunomodulators, or anti-TNF therapies should consider using vedolizumab, according to 2014 Toronto consensus guidelines.[30] Despite the European Crohn's and Colitis Organization's recommendation of Vedolizumab as a first-line treatment or for disease remission in the absence of anti-TNF treatment.[31]

In order to obtain and maintain remission, it was indicated that vedolizumab's method of action may call for a lengthier course of therapy in CD than in UC. At 10 weeks, vedolizumab is more efficacious than a placebo at inducing remission.The GEMINI 2 and GEMINI 3 studies looked into vedolizumab use in CD. 16,17 These studies showed fewer favourable outcomes in terms of clinical remission at 6 weeks as compared to the UC cohort. In GEMINI 3, no information on mucosal healing was acquired. [32]

When it came to achieving a clinical and steroid-free remission at 52 weeks, Vedolizumab outperformed the placebo in GEMINI 2. A later meta-analysis found that Vedolizumab is more effective than placebo at causing and maintaining clinical remission in Crohn's disease, although being less successful than Adalimumab in doing so.[33,34]

A 30-day postoperative surgical site infection occurred in 26% of CD patients who received vedolizumab within a year of major abdominal surgery, which is significantly higher than the rate among patients who did not receive either anti-TNF or biologic therapy. This finding comes from research by Lightner and colleagues.[35]A recent research concluded that there is no need for a washout period since utilising vedolizumab in patients undergoing non-intestinal surgery did not increase the incidence of postoperative infections, readmission, or reoperation when compared to the control group.[36] Comparing Vedolizumab to a placebo, the risk of gastroenteritis rises, although the likelihood of developing a severe Clostridium difficile infection is less than 0.6%. Despite the fact that these measures are not now commercially available, it was discovered in the GEMINI trials that vedolizumab levels and clinical efficacy had a favourable correlation. Anti-vedolizumab antibodies are present in 1-4.1% of patients, however GEMINI 3 results are consistently negative in all patients.

Data from the VISIBLE1 research presented at the UEGW 2018 conference showed that subcutaneous vedolizumab, administered at 108 mg every two weeks after intravenous (IV) vedolizumab 300 mg induction, was safe, efficient, and well tolerated as maintenance treatment in UC patients. Its safety and efficacy profile was similar to that of intravenous vedolizumab. In terms of mucosal healing and sustained clinical response, subcutaneously given vedolizumab performed better than the placebo. Patients who had used anti-TNF

inhibitors successfully and those who had not had significantly higher rates of clinical remission.[38]

5. VEDOLIZUMAB TREATMENT IN EMIs (EXTRAINTESTINAL MANIFESTATIONS)

Controlled trials have not specifically examined the efficacy of vedolizumab for treating EIMs in patients with IBD, although evidence is available from post hoc analysis of RCTs, prospective and retrospective cohort studies, case series, and case reports (Table 2). Even while musculoskeletal EIMs and PSC have been explored the most, there are currently few data available. Musculoskeletal EIMs were examined in a post hoc study of the Vedolizumab registration trials.[39]

For the treatment of musculoskeletal EIMs connected to disease activity, vedolizumab may be helpful. The registration trials employed the CDAI diaries and adverse event report forms to gather information on arthralgia and arthritis in CD, but only the latter in UC, making it hard to differentiate between the emergence of new EIMs and the deterioration of baseline EIMs. Comparable rates of long-lasting remission of articular symptoms were observed in both treatment groups, and vedolizumab decreased the incidence of new or worsening arthralgia/arthritis in CD patients compared to placebo.[40]

In CD patients receiving corticosteroids at baseline, regardless of the treatment group, the chance of developing new or worsening arthralgia/arthritis increased if the corticosteroid dosage was lowered. Patients who achieved corticosteroid-free status experienced arthralgia symptoms less frequently with vedolizumab compared with placebo. In UC patients, new or worsening arthritis or arthralgia occurred just as frequently with vedolizumab as with the placebo. Although vedolizumab and placebo had the same impact on individuals who were able to discontinue using corticosteroids, corticosteroid reduction increased the chance of articular symptoms, similar to CD. Sustained resolution of EIMs was associated with clinical remission in both CD and UC, in contrast to rates of new or worsening EIMs. Patients who had previously used TNF antagonists had a higher chance of developing new or worsened EIMs. In a multicentre prospective cohort research conducted in France, vedolizumab was linked to clinical remission and recent development of articular EIMs before it was used, and 44.7% (21/47) of patients with baseline arthralgia/arthritis obtained full remission after using vedolizumab.[41] Patients who had previously been given an AS diagnosis were more likely to experience new arthralgia or arthritis, which occurred in 13.8% (34/247) of the patients during the investigation. A separate cohort trial discovered that 39.5% (17/43) of patients had decreased articular symptoms compared to baseline after 10 weeks of vedolizumab therapy. This improvement was closely correlated with the underlying IBD's clinical outcome.[42]

Two investigations specifically compared the rate of de novo EIMs in individuals treated with vedolizumab versus those treated with TNF antagonists using a database of insurance claims and clinical note natural language processing.[43,44] The first study found that vedolizumab increased the chance of developing arthropathy in people with CD, but that there was no significant difference between vedolizumab and TNF antagonists in patients with UC.[45] The information on disease activity was not gathered for this investigation, which may have an influence on how outcomes for EIMs that mimic intestinal inflammation are interpreted. In the second study, there was no indication of an increased risk of arthralgia in those taking vedolizumab once disease-related variables were taken into account.[46] An important need for interpreting data from articular EIMs was identified by a single-center retrospective cohort study: only 17 of the 35 new musculoskeletal symptoms that 28.6% of patients (32/112) encountered were classified as inflammatory after rheumatological examination. The osteoarthritis that caused the remaining ones was blamed.[47]The majority of those who experienced incident articular EIMs after the introduction of vedolizumab had recently quit taking TNF antagonists, while EIMs were also seen in patients who had never taken a TNF antagonist.[48-50]

Study	**Extra-intestinal Manifestation**	**Sample Size**	**Study Design**	**Main Result**
Macaluso et al. [51]	Arthritis	Total 163 CD 84 UC 79	Prospective multicentre cohort study	39.5% (17/43) of those with active ankylosing spondylitis at baseline responded, with 13/28 showing periphery participation, 2/4 showing axial intervention, and 2/11 showing mixed complicity. Three individuals with active luminal IBD developed de novo ankylosing spondylitis.
Dupre et al.[52]	Arthritis	Total 112 CD 59 UC 49 IC 4	Retrospective single-center cohort study	9.8% of patient populations (11/12) developed axial or semi - periphery lower secondary level; 8/11 had active inflammatory bowel disease (IBD); 7/8 of these patient populations changed their psychotherapy, and the patient who remained improved with VDZ; in the 3/11 patient populations with non active inflammatory bowel disease, local corticosteroids, pain relievers, and continued VDZ led to improved

				performance.
Philips et al. [53]	Cutaneous	Total 11	several-center case series	In two-fourths of instances, erythema nodosum responds. Pyoderma gangrenosum: reaction in 0/1 instances Metastatic CD: Remission occurs in 1/3 of instances Remission in one out of one cases of leukocytoclasticvasculitis
Caron et al. [54]	PSC	Total 75 CD 26 UC 49	Retroactive cohort study involving many centres	ALP hasn't changed significantly.
Christensen et al. [55]	PSC	Total 34 CD 16 UC 18	Retroactive cohort study involving many centres	ALP hasn't changed significantly.
Tse et al. [56]	PSC	Total 27 CD 10 UC 16 IC 6	Retroactive cohort study involving many centres	ALP did not significantly alter, and 79% (19/24) of patients had highly radioactive stable illness at twelve months, which is commensurate with PSC's normal course.
Lynch et al [57]	PSC	Total 102 CD 30 UC 66 IBD-U 6	Retroactive cohort study involving many centres	There was a 20% decrease in ALP in 20% of patients (21/102) from 1.54 x ULN to 1.64 x ULN (P = 0.018);

Table 2. Overview of Studies with Vedolizumab in Extra intestinal Manifestation

AL- Alkaline phosphatase, CD- Crohn's disease, EIM- Extraintestinal manifestation, IBD-U- Inflammatory Bowel Disease Unclassified, IC- Indeterminate colitis, PL- Placebo, PSC-Primary sclerosing cholangitis, RCT- Randomized controlled trial, UC-Ulcerative colitis, ULN- Upper Limit of normal, VDZ-Vedolizumab

6. CLINICAL APPLICATIONS OF VEDOLIZUMABS

Vedolizumab was shown to be beneficial in the treatment of UC in the GEMINI-1 study, a phase III multi-center, managed, double-blind, non - randomized trial that investigated the effectiveness and safety of vedolizumab in individuals having active UC.[58] During the

initiation phase of the experiment, 521 patients (cohort 2) received open-label vedolizumab (300 mg) at weeks 0 and 2, although 374 subjects (cohort 1) were rough layout to undergo vedolizumab (300 mg) or placebo infusions. At week 6, patients receiving vedolizumab and those receiving a placebo, respectively, achieved the primary result (clinical response) in 47.1% and 25.5% of cases, respectively (p 0.001). At week 6, considerably more patients receiving vedolizumab than those receiving a placebo had clinical remission and mucosal healing (16.9% and 5.4%, and 40.9% and 24.8%, respectively; $p < 0.001$ for the comparison with placebo for both outcomes).Personnel to vedolizumab from both cohorts (n = 373) were randomly assigned to receive vedolizumab 300 mg or a placebo every 4 or 8 weeks for a maximum of 52 weeks during the maintenance phase of the experiment. At week 52, patients receiving vedolizumab had a higher likelihood of being in clinical remission than those receiving placebo (15.9%, p 0.001) (41.8% with every 8 weeks and 44.8% with every 4 weeks). Patients receiving vedolizumab had substantially greater rates of mucosal healing, glucocorticoid-free remission, and sustained (both weeks 6 and 52) clinical response and remission than those receiving placebo.[59] Vedolizumab is effective in treating UC patients, according to a Cochrane meta-analysis of four randomized clinical trials with a total of 606 volunteers.[60]Induction of clinical remission, clinical response, and endoscopic remission, as well as clinical remission at week 52 in week 6 responders (RR = 2.73, 95% CI 1.78-4.18) were all significantly better with vedolizumab than placebo, according to pooled analyses (relative risk [RR] = 0.86, 95% confidence interval [CI] 0.80-0.91).[61]There are very little data on the impact of vedolizumab on the histologic disease activity, despite the fact that histologic outcomes are increasingly examined in IBD studies. A little benefit was observed at week 52 compared to earlier time periods in a limited cohort of patients from the GEMINI 1 and LTS trials, where 55% (12/22) of patients with endoscopic healing also showed histologic healing.[62]Although a study comparing Adalimumab with vedolizumab in patients with moderate-to-severe UC is actively enrolling patients, results from head-to-head studies of vedolizumab with other medications are not yet available.[63-64]

In order to treat adult patients with moderately to severely active UC and CD who had an inadequate response, lost response, or intolerance to either conventional therapy or a TNF opponent, vedolizumab was granted approval by the European Medicines Agency and the US The Food and Drug Administration in 2014. Mainstream recommendations advise utilising vedolizumab as a first line biologic treatment when individuals do not react to corticosteroids or aminosalicylates.[65-67]

7. MECHANISM OF ACTION OF VEDOLIZUMAB

Circulating lymphocytes' cell-surface integrin’s and their endothelial cell-associated ligands interact to help lymphocytes securely stick to endothelial surfaces and then enter the mucosa through the Para-cellular pathway.[68] An integrin homodimer expressed on lymphocytes

interacts with mucosal address in cell adhesion molecule-1 (MAdCAM-1), which is expressed only on the endothelial surface of gut-associated lymphoid tissue and gastrointestinal tract. α4β7integrin and MAdCAM-1 adhere to the endothelial surface.[69] Targeted by Vedolizumab is the α4β7integrin. The antibody stops lymphocytes from emigrating from the vasculature to the gut by preventing the interaction between the α4β7integrin and MAdCAM-1. Vedolizumab, in contrast to Natalizumab, had no impact on interactions between the 41-integrin and VCAM-1, a molecule with a more widespread pattern of expression, including the CNS. By making this difference, a process that is thought to be required for the formation of PML—inhibition of lymphocyte trafficking to the CNS—is avoided.[70]

In a randomised, placebo-controlled, phase I study in healthy volunteers, the gut selectivity of vedolizumab was shown. The experiment examined the humoral immune system's response to antigens provided parenterally (intramuscular hepatitis B vaccination) and endotracheal (oral cholera vaccine).[71] Patients who were administered Vedolizumab experienced a reduced oral vaccination response, while antibody responses to the systemically delivered antigen were unaltered.[72]

A method to lower the intensity of UC and CD and maybe deliver a more established safety profiles has been proposed: the production of a monoclonal antibody that blocks the α4β7integrin:MAdCAM-1 interaction in the gastrointestinal system. To support this pharmacological concept, it was important to demonstrate selective binding of the α4β7 integrin by ACT-1, the animal anti-human α4β7 monoclonal antibodies through which vedolizumab was produced. Vedolizumab administration produced anti-inflammatory benefits and illness regression in a concrete evidence study utilising spontaneously colitic cotton-top tamarin monkeys.[73]

We make reference to vedolizumab (also known as LDP-02, MLN02, MLN0002, and MLN0002) jointly throughout the whole investigation, were developed as humanised versions of ACT-1 because their efficacy in the animal model made them more suitable for prolonged exposure in people with UC and CD. Influencing parameters was accomplished by attaching an IgG1 monoclonal to the receptor complex of ACT-1. The formulation procedure for later generations of vedolizumab was changed to address immunogenicity with an earlier version.[74] The Fc receptor-binding motif was altered to avoid the cytotoxicity connected to the fragment crystallisable [Fc] region, significantly reduced counterbalance and specific antibodies cellular apoptotic activities. Vedolizumab is a non-lytic antibody, as evidenced by the absence of cytotoxicity in both laboratory and real-world settings.[75] Vedolizumab only binds to the gut-tropic α4β7 integrin; it does not bind to the functionally different α4 β1 or E7 integrin's or any other α4 or β7 heterodimers.[76,77]

The vedolizumab epitope's location inside the 7 chains of the α4β7 heterodimer was discovered by X-ray diffraction, which also confirmed the vedolizumab's specificity for α4β7fibronectin.[78] Vedolizumab's lack of specificity for the integrin's α4β1 or E-7 theoretically has the benefit of preventing adverse effects from occurring beyond the gastrointestinal system, where these integrin's may be more important. For illustrate, α4β1 integrin controls the movement of leukocytes throughout a variety of organs and, in particularly, the migration of T cells to aggressive regions inside the CNS.[79]As a result, inhibiting the α4β1 integrin's physiological activity can put patients at risk for major side effects including PML development, as was shown with Natalizumab.[80,81]Vedolizumab was tested in a preclinical study on non-human animals to see how it affected their internal and external health, the drug's gut selectivity was shown.[82]

It is consistent with a gut-selective profile that vedolizumab, demonstrated no macroscopic or histological effects on any regions outside the intestinal lumen in cynomolgus primates when continuously administered. In the ileum, there was a general decline in mononuclear cell infiltration and a decline in lymphocytes that represented the 7 integrin, which correlated inversely with an upsurge in memory T lymphocytes that identified the 47 transcription factor in the micro vascular. The vascular cell groupings showed no further alterations.[83]

8. VEDOLIZUMAB STRUCTURE

IgG1 monoclonal antibody vedolizumab is a recombinant humanised form of the substance made in Chinese hamster ovary cells.[84]Vedolizumab was made by fusing the Act-1 frequency to a standard human IgG1 scaffolds. Act-1 is a humanized monoclonal that targets human α4β7. Additionally, two mutations were added to the vedolizumab Fc region, which reduced several Fc-mediated activities including cytotoxicity.[85]Vedolizumab is composed of two polypeptide chains of the kappa subclass, two heavy chains, and two shackles joined by two disulphide bonds, and it has a Y-structure that really is typical of cells of the immune system. Vedolizumab has a molecular weight of around 147 kDa.[86]

9. CONCLUSION

The mechanism of VDZ is done by binding on α4β7 integrin which results in alteration of gene expression of blood monocytes, thereby inhibiting their ability to enter the intestinal epithelium.The Vedolizumab are safe for systemic treatment because it do not have undesirable safety profile.

In fact, the preference for the gastrointestinal system is shown in the most recent safety study supporting vedolizumab. Coming soon is a thorough assessment of the safety information from six clinical studies including vedolizumab.[87]

The mechanism through which Vedolizumab inhibits gut-homing memory T cells from migrating into the sub mucosa of the gastrointestinal tract is the same as that employed by other monoclonal antibodies that are approved for the treatment of UC and CD. Vedolizumab reduces the affinity of 47 integrin for its ligand MAdCAM-1, but does not completely eliminate it.[88] through thread Pharmacovigilance and risk assessment programmes, the long-term safety of vedolizumab is being monitored. At the conclusion of the on-going phase 3 GEMINI protracted safety study [ClinicalTrials.gov ID, NCT00790933] in 2016, the much awaited information regarding the appropriate systematic of long-term sustained vedolizumab medicine will really be made public. Vedolizumab's gut-selective mode of action, which offers a special alternative therapeutic approach for the treatment of UC and CD, is significant since it exhibits effectiveness while preserving a favourable safety profile.[89-90]

RFERENCE-

1. Talley, N. J., & O'Connor, S. (2013). *Clinical examination: a systematic guide to physical diagnosis*. Elsevier Health Sciences.

2. Baumgart, D. C., &Sandborn, W. J. (2012). Crohn's disease. *The Lancet*, *380*(9853), 1590-1605.

3. Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L., &Bonovas, S. (2014). Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. *Annals of internal medicine*, *160*(10), 704-711.

4.Soler, D., Chapman, T., Yang, L. L., Wyant, T., Egan, R., &Fedyk, E. R. (2009). The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. *Journal of Pharmacology and Experimental Therapeutics*, *330*(3), 864-875.

5. Pappas, A. L., & Hanna, S. (2015). Entyvio by Takeda Pharmaceuticals.

6. Juneja, M., Baidoo, L., Schwartz, M. B., Barrie, A., Regueiro, M., Dunn, M., &Binion, D. G. (2012). Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. *Digestive diseases and sciences*, *57*(9), 2408-2415.

7. Sales-Campos, H., Basso, P. J., Alves, V. B. F., Fonseca, M. T. C., Bonfá, G., Nardini, V., & Cardoso, C. R. B. (2014). Classical and recent advances in the treatment of inflammatory bowel diseases. *Brazilian Journal of Medical and Biological Research*, *48*, 96-107.

8. Soler, D., Chapman, T., Yang, L. L., Wyant, T., Egan, R., &Fedyk, E. R. (2009). The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. *Journal of Pharmacology and Experimental Therapeutics*, *330*(3), 864-875.

9. Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J. F., Sandborn, W. J., ...& Parikh, A. (2013). Vedolizumab as induction and maintenance therapy for ulcerative colitis. *New England Journal of Medicine*, *369*(8), 699-710.

10. Parikh, A., Fox, I., Leach, T., Xu, J., Scholz, C., Patella, M., &Feagan, B. G. (2013). Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. *Inflammatory Bowel Diseases*, *19*(8), 1691-1699.

11. Moran, G. W., Dubeau, M. F., Kaplan, G. G., Yang, H., Seow, C. H., Fedorak, R. N., ... & Alberta Inflammatory Bowel Disease Consortium. (2014). Phenotypic features of Crohn's disease associated with failure of medical treatment. *Clinical Gastroenterology and Hepatology*, *12*(3), 434-442.

12. Barré, A., Colombel, J. F., &Ungaro, R. (2018). predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. *Alimentary pharmacology & therapeutics*, *47*(7), 896-905.

13. Singh, H., Grewal, N., Arora, E., Kumar, H., &Kakkar, A. K. (2016). Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. *Journal of Natural Science, Biology, and Medicine*, *7*(1), 4.

14. Neurath, M. F. (2019). Targeting immune cell circuits and trafficking in inflammatory bowel disease. *Nature immunology*, *20*(8), 970-979.

15. Lichtenstein, G. R. (2013). Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. *Therapeutic advances in gastroenterology*, *6*(4), 269-293.

16. Amiot, A., &Peyrin-Biroulet, L. (2015). Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. *Therapeutic Advances in Gastroenterology*, *8*(2), 66-82.

17. Steinman, L. (2005). Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. *Nature reviews Drug discovery*, *4*(6), 510-518.

18. Ramadas, A. V., Gunesh, S., Thomas, G. A. O., Williams, G. T., & Hawthorne, A. B. (2010). Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. *Gut*, *59*(9), 1200-1206.

19. Rungoe, C., Langholz, E., Andersson, M., Basit, S., Nielsen, N. M., Wohlfahrt, J., & Jess, T. (2014). Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011. *Gut*, *63*(10), 1607-1616.

18. Freeman, H. J. (2014). Natural history and long-term clinical course of Crohn's disease. *World journal of gastroenterology: WJG*, *20*(1), 31.

19. Carpio, D., Barreiro-de Acosta, M., Echarri, A., Pereira, S., Castro, J., Ferreiro, R., & Lorenzo, A. (2015). Influence of urban/rural and coastal/inland environment on the prevalence, phenotype, and clinical course of inflammatory bowel disease patients from northwest of Spain: a cross-sectional study. *European Journal of Gastroenterology &Hepatology*, *27*(9), 1030-1037.

20. Mayberry, J. F., Lobo, A., Ford, A. C., Thomas, A., & Guideline Development Group. (2013). NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. *Alimentary pharmacology & therapeutics*, *37*(2), 195-203.

21. Bodelier, A. G., Jonkers, D., van den Heuvel, T., de Boer, E., Hameeteman, W., Masclee, A. A., &Pierik, M. J. (2017). High percentage of IBD patients with indefinite fecalcalprotectin levels: additional value of a combination score. *Digestive diseases and sciences*, *62*(2), 465-472.

22. Vuitton, L., Koch, S., &Peyrin-Biroulet, L. (2013). Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment. *Current drug targets*, *14*(12), 1385-1391.

23. Sandborn, W. J., Gasink, C., Gao, L. L., Blank, M. A., Johanns, J., Guzzo, C., ... &Feagan, B. G. (2012). Ustekinumab induction and maintenance therapy in refractory Crohn's disease. *New England Journal of Medicine*, *367*(16), 1519-1528.

24. Abdalla, M. I., &Herfarth, H. (2016). Budesonide for the treatment of ulcerative colitis. *Expert opinion on pharmacotherapy*, *17*(11), 1549-1559.

25. Ford, A. C., Sandborn, W. J., Khan, K. J., Hanauer, S. B., Talley, N. J., &Moayyedi, P. (2011). Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. *Official journal of the American College of Gastroenterology| ACG*, *106*(4), 644-659.

25. Ford, A. C., Sandborn, W. J., Khan, K. J., Hanauer, S. B., Talley, N. J., &Moayyedi, P. (2011). Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. *Official journal of the American College of Gastroenterology| ACG*, *106*(4), 644-659.

26. Ramadas, A. V., Gunesh, S., Thomas, G. A. O., Williams, G. T., & Hawthorne, A. B. (2010). Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. *Gut*, *59*(9), 1200-1206.

27. Rungoe, C., Langholz, E., Andersson, M., Basit, S., Nielsen, N. M., Wohlfahrt, J., & Jess, T. (2014). Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011. *Gut*, *63*(10), 1607-1616.

28. Brown, E. G., Wood, L., & Wood, S. (1999). The medical dictionary for regulatory activities (MedDRA). *Drug safety*, *20*(2), 109-117.

29. Danese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L., &Bonovas, S. (2014). Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. *Annals of internal medicine*, *160*(10), 704-711.

30. Bressler, B., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., ... & Williams, C. (2015). Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. *Gastroenterology*, *148*(5), 1035-1058.

31. Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., ...&Carbonnel, F. (2017). Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. *Journal of Crohn's and Colitis*, *11*(7), 769-784.

32. Sands, B. E., Feagan, B. G., Rutgeerts, P., Colombel, J. F., Sandborn, W. J., Sy, R., ... &Hanauer, S. (2014). Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. *Gastroenterology*, *147*(3), 618-627.

33. Hazlewood, G. S., Rezaie, A., Borman, M., Panaccione, R., Ghosh, S., Seow, C. H., ...& Kaplan, G. G. (2015). Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. *Gastroenterology*, *148*(2), 344-354.

34. Katz, S., &Pardi, D. S. (2011). Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). *Official journal of the American College of Gastroenterology| ACG*, *106*(11), 1889-1897.

35. Hazel, K., & O'Connor, A. (2020). Emerging treatments for inflammatory bowel disease. *Therapeutic advances in chronic disease*, *11*, 2040622319899297.

36. Almutairdi, A. A., Kotze, P. G., Ma, C., McKenna, N. P., Raffals, L. H., Loftus, E. V., ... & Lightner, A. L. (2018). Sa1692-Vedolizumab and Early Postoperative Complications in Nonintestinal Surgery: A Case-Matched Analysis. *Gastroenterology*, *154*(6), S-358.

37. Colombel, J. F., Sands, B. E., Rutgeerts, P., Sandborn, W., Danese, S., D'Haens, G., ...&Feagan, B. G. (2017). The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut*, *66*(5), 839-851.

38. Baird, A. D. (2011, May). Exstrophy in the adolescent and young adult population.In *Seminars in Pediatric Surgery* (Vol. 20, No. 2, pp. 109-112). WB Saunders.

39. Feagan, B. G., Sandborn, W. J., Colombel, J. F., Byrne, S. O., Khalid, J. M., Kempf, C., ... & Rubin, D. T. (2019). Incidence of arthritis/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials. *Journal of Crohn's and Colitis*, *13*(1), 50-57.

40. Feagan, B. G., Sandborn, W. J., Colombel, J. F., Byrne, S. O., Khalid, J. M., Kempf, C., ... & Rubin, D. T. (2019). Incidence of arthritis/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials. *Journal of Crohn's and Colitis*, *13*(1), 50-57.

41. Tadbiri, S., Peyrin- Biroulet, L., Serrero, M., Filippi, J., Pariente, B., Roblin, X., ...& Al Qaddi, J. (2018). Impact of vedolizumab therapy on extra- intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV- IBD cohort. *Alimentary pharmacology & therapeutics*, *47*(4), 485-493.

42. Macaluso, F. S., Orlando, R., Fries, W., Scolaro, M., Magnano, A., Pluchino, D., ...&Orlando, A. (2018). The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. *Digestive and Liver Disease*, *50*(7), 675-681.

43. Dubinsky, M. C., Cross, R. K., Sandborn, W. J., Long, M., Song, X., Shi, N., ...& Wang, A. (2018). Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease. *Inflammatory bowel diseases*, *24*(9), 1876-1882.

44. Cai, T., Lin, T. C., Bond, A., Huang, J., Kane-Wanger, G., Cagan, A., ...& Liao, K. P. (2018). The association between arthralgia and vedolizumab using natural language processing. *Inflammatory bowel diseases*, *24*(10), 2242-2246.

45. Dubinsky, M. C., Cross, R. K., Sandborn, W. J., Long, M., Song, X., Shi, N., ...& Wang, A. (2018). Extraintestinal manifestations in vedolizumab and anti-TNF-treated patients with inflammatory bowel disease. *Inflammatory bowel diseases*, *24*(9), 1876-1882.

46. Cai, T., Lin, T. C., Bond, A., Huang, J., Kane-Wanger, G., Cagan, A., ...& Liao, K. P. (2018). The association between arthralgia and vedolizumab using natural language processing. *Inflammatory bowel diseases*, *24*(10), 2242-2246.

47. Hanzel, J., Ma, C., Casteele, N. V., Khanna, R., Jairath, V., &Feagan, B. G. (2021). Vedolizumab and extraintestinal manifestations in inflammatory bowel disease. *Drugs*, *81*(3), 333-347.

48. Tamanini, S., Fredi, M., Crisafulli, F., Lazzaroni, M. G., Tincani, A., &Franceschini, F. (2019). Letter to editor: new onset/recurrence of inflammatory arthralgia/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease. *Clinical Rheumatology*, *38*(2), 609-610.

49. Dubash, S., Marianayagam, T., Tinazzi, I., Al-Araimi, T., Pagnoux, C., Weizman, A. V., ...&McGonagle, D. (2019). Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease. *Rheumatology*, *58*(6), 963-968.

50. Varkas, G., Thevissen, K., De Brabanter, G., Van Praet, L., Czul-Gurdian, F., Cypers, H., ...&Elewaut, D. (2017). An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series. *Annals of the rheumatic diseases*, *76*(5), 878-881.

51. Macaluso, F. S., Orlando, R., Fries, W., Scolaro, M., Magnano, A., Pluchino, D., ...&Orlando, A. (2018). The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. *Digestive and Liver Disease*, *50*(7), 675-681.

52. Hanzel, J., Ma, C., Casteele, N. V., Khanna, R., Jairath, V., &Feagan, B. G. (2021). Vedolizumab and extraintestinal manifestations in inflammatory bowel disease. *Drugs*, *81*(3), 333-347.

53. Phillips, F. M., Verstockt, B., Sebastian, S., Ribaldone, D., Vavricka, S., Katsanos, K., ...&Kopylov, U. (2020). Inflammatory cutaneous lesions in inflammatory bowel disease treated with vedolizumab or ustekinumab: an ECCO CONFER multicentre case series. *Journal of Crohn's and Colitis*, *14*(10), 1488-1493.

54. Caron, B., Peyrin-Biroulet, L., Pariente, B., Bouhnik, Y., Seksik, P., Bouguen, G., ...&Amiot, A. (2019). Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID multicentre cohort study. *Journal of Crohn's and Colitis*, *13*(10), 1239-1247.

55. Christensen, B., Micic, D., Gibson, P. R., Yarur, A., Bellaguarda, E., Corsello, P., ...& Rubin, D. T. (2018). Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. *Alimentary pharmacology & therapeutics*, *47*(6), 753-762.

56. Tse, C. S., Loftus Jr, E. V., Raffals, L. E., Gossard, A. A., & Lightner, A. L. (2018). Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease. *Alimentary pharmacology & therapeutics*, *48*(2), 190-195.

57. Lynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., ... & International Primary Sclerosing Cholangitis Study Group. (2020). Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. *Clinical Gastroenterology and Hepatology*, *18*(1), 179-187.

58. Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J. F., Sandborn, W. J., ...& Parikh, A. (2013). Vedolizumab as induction and maintenance therapy for ulcerative colitis. *New England Journal of Medicine*, *369*(8), 699-710.

59. Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J. F., Sandborn, W. J., ...& Parikh, A. (2013). Vedolizumab as induction and maintenance therapy for ulcerative colitis. *New England Journal of Medicine*, *369*(8), 699-710.

60. Mosli, M. H., MacDonald, J. K., Bickston, S. J., Behm, B. W., Tsoulis, D. J., Cheng, J., ... &Feagan, B. G. (2015). Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. *Inflammatory bowel diseases*, *21*(5), 1151-1159.

61. Mosli, M. H., MacDonald, J. K., Bickston, S. J., Behm, B. W., Tsoulis, D. J., Cheng, J., ... &Feagan, B. G. (2015). Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. *Inflammatory bowel diseases*, *21*(5), 1151-1159.

62. Arijs, I., De Hertogh, G., Lemmens, B., Van Lommel, L., de Bruyn, M., Vanhove, W., ...&Vermeire, S. (2018). Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. *Gut*, *67*(1), 43-52.

63. Debels, L., Schoonjans, C., Valori, R., Anderson, J., & Tate, D. J. LB01| THE ACCURACY OF HUMAN DETECTION OF SUBMUCOSAL INVASIVE CANCER–ANALYSIS OF 739 INDIVIDUAL ASSESSMENTS OF LARGE NON- PEDUNCULATED COLORECTAL POLYPS (LNPCPS) USING A NOVEL CLINICAL DECISION SUPPORT TOOL.

64. Abong, J. M., Mallillin, J. M. I., Agcaoili-De Jesus, M. S., Mondragon, A. V., Aleta, L. T. A., Nano, A. L. M., ... &Ybiernas-Gallinero, C. P. Contributors: Fellows and Diplomates of the.

65. Bressler, B., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., ... &Feagan, B. (2015). Toronto Ulcerative Colitis Consensus Group. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. *Gastroenterology*, *148*(5), 1035-1058.

66. Armuzzi, A., Gionchetti, P., Daperno, M., Danese, S., Orlando, A., LiaScribano, M., ...&Rizzello, F. (2016). GIVI (GruppoItalianosu Vedolizumab nelle IBD) Group.Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. *Dig Liver Dis*, *48*(4), 360-70.

67. Dassopoulos, T., Cohen, R. D., Scherl, E. J., Schwartz, R. M., Kosinski, L., &Regueiro, M. D. (2015). Ulcerative colitis care pathway. *Gastroenterology*, *149*(1), 238-245.

68. Novak, G., Hindryckx, P., Khanna, R., Jairath, V., &Feagan, B. G. (2017). The safety of vedolizumab for the treatment of ulcerative colitis. *Expert Opinion on Drug Safety*, *16*(4), 501-507.

69. Briskin, M., Winsor-Hines, D., Shyjan, A., Cochran, N., Bloom, S., Wilson, J., ...&Ringler, D. J. (1997). Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. *The American journal of pathology*, *151*(1), 97.

70. Novak, G., Hindryckx, P., Khanna, R., Jairath, V., &Feagan, B. G. (2017). The safety of vedolizumab for the treatment of ulcerative colitis. *Expert Opinion on Drug Safety*, *16*(4), 501-507.

71. Wyant, T., Leach, T., Sankoh, S., Wang, Y., Paolino, J., Pasetti, M. F., ...& Parikh, A. (2015). Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. *Gut*, *64*(1), 77-83.

72. Wyant, T., Leach, T., Sankoh, S., Wang, Y., Paolino, J., Pasetti, M. F., ...& Parikh, A. (2015). Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. *Gut*, *64*(1), 77-83.

73. Hesterberg, P. E., Winsor-Hines, D. A. W. N., Briskin, M. J., Soler-Ferran, D. U. L. C. E., Merrill, C. H. R. I. S. T. O. P. H. E. R., Mackay, C. R., ... &Ringler, D. J. (1996). Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. *Gastroenterology*, *111*(5), 1373-1380.

74. Parikh, A., Leach, T., Wyant, T., Scholz, C., Sankoh, S., Mould, D. R., ...&Feagan, B. G. (2012). Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. *Inflammatory bowel diseases*, *18*(8), 1470-1479.

75. Wyant, T., Yang, L., &Fedyk, E. (2013, November). In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes.In *MAbs* (Vol. 5, No. 6, pp. 842-850).Taylor & Francis.

76. Schweighoffer, T., Tanaka, Y., Tidswell, M., Erle, D. J., Horgan, K. J., Luce, G. E., ...& Shaw, S. (1993). Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophism. *The Journal of Immunology*, *151*(2), 717-729.

77. Soler, D., Chapman, T., Yang, L. L., Wyant, T., Egan, R., &Fedyk, E. R. (2009). The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. *Journal of Pharmacology and Experimental Therapeutics*, *330*(3), 864-875.

78. Yu, Y., Zhu, J., Mi, L. Z., Walz, T., Sun, H., Chen, J., & Springer, T. A. (2012). Structural specializations of α4β7, an integrin that mediates rolling adhesion. *Journal of Cell Biology*, *196*(1), 131-146.

79. Haanstra, K. G., Hofman, S. O., Estêvão, D. M. L., Blezer, E. L., Bauer, J., Yang, L. L., ... &Fedyk, E. R. (2013). Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. *The Journal of Immunology*, *190*(5), 1961-1973.

80. Berger, J. R. (2006). Natalizumab and progressive multifocal leucoencephalopathy. *Annals of the rheumatic diseases*, *65*(suppl 3), iii48-iii53.

81. Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., ...&Bozic, C. (2012). Risk of natalizumab-associated progressive multifocal leukoencephalopathy. *New England Journal of Medicine*, *366*(20), 1870-1880.

82. Fedyk, E. R., Wyant, T., Yang, L. L., Csizmadia, V., Burke, K., Yang, H., &Kadambi, V. J. (2012). Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. *Inflammatory bowel diseases*, *18*(11), 2107-2119.

83. Fedyk, E. R., Wyant, T., Yang, L. L., Csizmadia, V., Burke, K., Yang, H., &Kadambi, V. J. (2012). Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. *Inflammatory bowel diseases*, *18*(11), 2107-2119.

84. Pappas, A. L., & Hanna, S. (2015). Entyvio by Takeda Pharmaceuticals.

85. Wyant, T., Yang, L., &Fedyk, E. (2013, November). In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes.In *MAbs* (Vol. 5, No. 6, pp. 842-850).Taylor & Francis.

86. Pappas, A. L., & Hanna, S. (2015). Entyvio by Takeda Pharmaceuticals.

87. Colombel, J. F., Sands, B. E., Rutgeerts, P., Sandborn, W., Danese, S., D'Haens, G., ...&Feagan, B. G. (2017). The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut*, *66*(5), 839-851.

88. Soler, D., Chapman, T., Yang, L. L., Wyant, T., Egan, R., &Fedyk, E. R. (2009). The binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseases. *Journal of Pharmacology and Experimental Therapeutics*, *330*(3), 864-875.

89. Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J. F., Sandborn, W. J., ...& Parikh, A. (2013). Vedolizumab as induction and maintenance therapy for ulcerative colitis. *New England Journal of Medicine*, *369*(8), 699-710.

90. Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J. F., Sands, B. E., ...& Parikh, A. (2013). Vedolizumab as induction and maintenance therapy for Crohn's disease. *New England Journal of Medicine*, *369*(8), 711-721.